Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure

AIDS

Volumn 12, Issue 10, 1998, Pages

  Deeks, Steven G ^a,e   Grant, Robert M ^a,b   Beatty, George W ^a   Horton, Christopher ^b   Detmer, Jill ^c   Eastman, Scott ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Synteni Inc   (United States)

^e SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Antiretroviral therapy; Protease inhibitors; Resistance

Indexed keywords

INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL ARTICLE; DNA DETERMINATION; DRUG COMBINATION; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MALE; POINT MUTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; COHORT STUDIES; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; NUCLEIC ACID HYBRIDIZATION; POINT MUTATION; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RITONAVIR; SAQUINAVIR; TREATMENT FAILURE; VIRAL LOAD;

EID: 0032500125     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199810000-00002     Document Type: Article

References (15)

1. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infections and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
2. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-789.
3. Deeks S, Loftus R, Cohen P, Chin S, Grant RM: Incidence and predictors of virologic failure to indinavir (IDV) or/and ritonavir (RTV) in an urban health clinic. 37th International Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [abstract LB-2].
4. Fätkenheuer G, Theisen A, Rockstroh J, et al.: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.
5. Demeter L, Hughes M, Fischl M, et al.: Predictors of virologic and clinical responses to indinavir (IDV)+ZDV+3TC or ZDV+3TC. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 509].
6. Department of Health and Human Services, Panel on Clinical Practices for Treatment of HIV Infection: Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 31 March 1998 document. http://www.hivatis.org.
7. Carpenter CC, Fischl M, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA Panel. JAMA 1997, 277:1962-1969.
8. Condra JH, Holder DJ, Schlief WA, et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996, 70:8270-8276.
9. Merry C, Barry MG, Mulcahy F, et al.: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11:F29-F33.
10. Cameron W, Sun E, Markowitz M, et al.: Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThB934].
11. Lorenzi P, Yerly S, Abderrakim K, et al.: Toxicity, efficacy, plasma concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS 1997, 11:F95-F99.
12. Eastman PS, Boyer E, Mole L, Kolberg J, Urdea M, Holodniy M: Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance. J Clin Microbiol 1995, 33:2777-2780.
13. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV-1 protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
14. Gallant JE, Hall C, Barnett S, Raines C: Ritonavir/saquinavir (RTV/SQV) as salvage therapy after failure of initial protease inhibitor (PI) regimen. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 427].
15. Molla A, Korneyeva M, Chernyavskiy T, et al.: Characterization of HIV-1 protease mutations, compliance and drug concentrations in patients who have an HIV RNA rebound on ritonavir-saquinavir. International Workshop on HIV Resistance, Treatment Strategies, and Eradication. St Petersburg, June 1997 [abstract 83].